Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF
Aaron Logan, MD PhD, conveyed his gratitude to the event organizers and acknowledged the valuable input of different perspectives at the meeting. He highlighted the critical role of assessing minimal residual disease (MRD) in leukemia treatment strategies. Drawing on data from various studies, Dr. Logan underscored how MRD presence or absence can accurately predict survival outcomes in patients undergoing therapy for leukemia. However, he also acknowledged the limitations of MRD assessments, as they don’t always perfectly predict relapse or remission. He discussed the importance of precise MRD measurement, delving into various techniques with differing sensitivities.
Dr. Logan showcased evidence supporting the efficacy of blinatumomab in patients achieving MRD negativity below certain thresholds. He posed thought-provoking questions about the necessity of maintaining prolonged therapy regimens and proposed potential adaptations based on MRD levels and observed outcomes.
